A 15.9‐month reduction in mean OS (log‐rank, P < 0.002) and 19.5‐month reduction in mean DFS (log‐rank, P < 0.002) were observed in patients with ZEB2‐positive tumours when compared to ZEB2‐negative ones (Fig 1C). This evidence concerns the gene ZEB2 and neoplasm.